A kind of glucosamine composition for inhalation and its preparation method and application
By preparing an inhalation composition containing glucosamine compounds with specific structures, the gastrointestinal adverse reactions of oral glucosamine and the particle size distribution of inhaled preparations are solved, and efficient and safe targeted drug administration is achieved, suitable for osteoarthritis and antiviral treatment.
Patent Information
- Application Number
- CN202410076419.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-18
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-01-18
AI Technical Summary
The existing oral glucosamine treatment has gastrointestinal adverse reactions, and inhaled preparations have challenges in particle size distribution and compatibility, affecting the targeting and effectiveness of the drug.
By adjusting concentration, osmotic pressure, pH value and particle size distribution, a solution suitable for atomized administration is prepared by using an inhalation composition containing a glucosamine compound of a specific structure and its pharmaceutically acceptable salts and carriers. Ensure high deposition effect and bioavailability of the drug in the lungs and lower respiratory tract.
It significantly improves the deposition effect and bioavailability of drugs in the lungs and lower respiratory tract, reduces systemic drug exposure and gastrointestinal adverse reactions, improves the effectiveness, safety and convenience of drugs, and is suitable for swallowing in the elderly and children. Difficult populations, with antiviral activity and high stability.
Smart Images

Figure CN117860712B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a glucosamine composition for inhalation, a preparation method thereof, and applications thereof. Background Art
[0002] D-glucosamine is a natural amino polysaccharide that stimulates chondrocytes to produce normal polymeric proteoglycans and inhibits enzymes that damage cartilage (collagenase and phospholipase A2). It also prevents the production of superoxide free radicals that damage cells, slowing the progression of osteoarthritis, improving joint mobility, and relieving pain. Glucosamine hydrochloride is widely used for the prevention and treatment of systemic osteoarthritis (including the knee, hip, spine, shoulder, hand, wrist, ankle, etc.), and its safety and effectiveness have been widely verified. However, oral glucosamine is associated with gastrointestinal adverse reactions.
[0003] Inhalation preparations are liquid or solid preparations that dissolve or disperse the drug in a medium and then deliver it to the lungs in the form of an aerosol or vapor, thereby exerting a local or systemic effect. Inhalation preparations include inhalation aerosols, inhalation powders, inhalation sprays, inhalation liquid preparations, and preparations that can be converted into vapor. Inhalation liquid preparations are atomized into droplets of approximately 3μm by a compressor and a nebulizer cup. The patient inhales the droplets through a mouthpiece or mask, achieving drug administration during normal breathing. No special coordination or suction strength requirements are required, making them more suitable for specific populations such as children, the elderly, and those with impaired respiratory function.
[0004] Solution-type inhalation preparations suitable for nebulization need to meet some basic properties. The first is sterility: sterile media are used during the preparation process to ensure that the preparation is sterile; second, low viscosity liquid and low surface tension: the preparation should have suitable fluidity to form fine droplets during the nebulization process; third, pH 3-10 to maintain a suitable physiological environment; fourth, suitable droplet size: the preparation should be able to form droplets with an average diameter of 1μm-5μm so that it can penetrate into different parts of the respiratory tract; fifth, suitable administration method: the preparation should be able to be effectively administered through a nebulizer or other device; sixth, no local irritation: the preparation should try to avoid local irritation during administration to ensure the comfort and safety of the patient; seventh, good compatibility: the drug in the preparation should have good compatibility with the packaging material or administration device such as nebulizer to avoid interaction between the drug and the packaging material or device. In inhalation preparations, the aerodynamic size distribution of atomized droplets is the primary factor influencing their efficacy and site of action. Droplets of different sizes deposit in different locations within the respiratory tract, such as the throat, trachea, bronchi, and alveoli. Generally speaking, the smaller the particle size, the longer the droplets remain suspended in the air, allowing the drug to be delivered deeper into the respiratory tract. Summary of the Invention
[0005] The object of the present invention is to provide a composition for inhalation, which contains a glucosamine compound (hereinafter referred to as a glucosamine compound) having a structure shown in Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
[0006]
[0007] wherein R and R' are the same or different and are each independently selected from hydrogen, a substituted or unsubstituted C1-C8 alkyl group, a substituted or unsubstituted C1-C8 alkylcarbonyl group, a substituted or unsubstituted C6-C15 arylcarbonyl group, a substituted or unsubstituted C6-C15 aryloxycarbonyl group, or a substituted or unsaturated 5-membered or 6-membered heterocyclylaminocarbonyl group containing 1 to 3 heteroatoms selected from N, O and S.
[0008] In the preferred technical solution of the present invention, the "substituted" means that the substituent further contains 1 or 2 substituents selected from methyl, ethyl, propyl, methoxy, ethoxy, propoxy, methyl formate, ethyl formate, propyl formate, fluorine and chlorine.
[0009] In a preferred technical solution of the present invention, the substituents R and R' are the same or different and are independently selected from hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkylcarbonyl, substituted or unsubstituted C6-C10 arylcarbonyl, substituted or unsubstituted C6-C10 aryloxycarbonyl.
[0010] In a preferred technical solution of the present invention, the substituents R and R' are the same or different and are independently selected from hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkylcarbonyl, substituted or unsubstituted C6-C8 arylcarbonyl, substituted or unsubstituted C6-C8 aryloxycarbonyl.
[0011] In a preferred technical solution of the present invention, the substituents R and R' are each independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, isobutylcarbonyl, tert-butylcarbonyl, phenylcarbonyl, methylphenylcarbonyl, ethylphenylcarbonyl, propylphenylcarbonyl, isopropylphenylcarbonyl, n-butylphenylcarbonyl, isobutylphenylcarbonyl, tert-butylphenylcarbonyl, naphthylcarbonyl, methylnaphthylcarbonyl, ethylnaphthylcarbonyl, propylnaphthylcarbonyl, isopropylnaphthylcarbonyl, n-butylnaphthylcarbonyl, isobutylnaphthylcarbonyl, and tert-butylnaphthylcarbonyl.
[0012] In the preferred technical solution of the present invention, the glucosamine compound is selected from any one or a combination of compounds 1-6.
[0013]
[0014] In a preferred technical solution of the present invention, the pharmaceutically acceptable salt is selected from any one of hydrochloride, sulfate, nitrate, aminosulfonate, phosphate, citrate, tartrate, lactate, acetate, benzenesulfonate, p-toluenesulfonate, methanesulfonate, naphthalenesulfonate, ethanesulfonate, naphthalenedisulfonate, maleate, malate, fumarate, succinate, oxalate, and salicylate, or a combination thereof.
[0015] In a preferred technical solution of the present invention, the inhalation composition is selected from any one of a solid preparation or a liquid preparation (solution).
[0016] In a preferred technical solution of the present invention, the pharmaceutically acceptable carrier is selected from any one of an osmotic pressure regulator, a stabilizer, a pH regulator, a solvent, and a lyoprotectant, or a combination thereof.
[0017] In a preferred technical solution of the present invention, the concentration of the glucosamine compound contained in the solution is 5 mg / ml-50 mg / ml, preferably 7.5 mg / ml-40 mg / ml, and more preferably 15 mg / ml-30 mg / ml.
[0018] In a preferred technical solution of the present invention, the osmotic pressure regulator is selected from any one of sodium chloride, potassium chloride, mannitol, glycerol, or a combination thereof.
[0019] In a preferred technical solution of the present invention, the osmotic pressure of the solution is 280mOsm / L-320mOsm / L.
[0020] In a preferred technical solution of the present invention, the stabilizer is selected from any one of disodium edetate, sodium sulfite, sodium metabisulfite, sodium bisulfite, vitamin C, ascorbyl palmitate, glycine, tryptophan, and lysine, or a combination thereof.
[0021] In a preferred technical solution of the present invention, the concentration of the stabilizer is 0.01-15 mg / ml, preferably 0.03-10 mg / ml, and more preferably 0.05-5 mg / ml.
[0022] In a preferred technical solution of the present invention, the pH regulator is selected from any one of sodium hydroxide, hydrochloric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate, citric acid, sodium citrate, citric acid, sodium citrate, malic acid, sodium malate, or a combination thereof.
[0023] In a preferred technical solution of the present invention, the solution has a pH of 3.0-8.0, preferably pH 4.0-7.5, and more preferably pH 5.0-7.0.
[0024] In a preferred technical solution of the present invention, the solvent is selected from any one of water, water for injection or a mixed solvent consisting of water and other co-solvents.
[0025] In a preferred technical solution of the present invention, after the solution is atomized, the mass median aerodynamic diameter (MMAD) is 2 μm-5 μm.
[0026] In a preferred technical solution of the present invention, after the solution is atomized, the fine particle dosage (FPF, <5 μm) is 30%-70%.
[0027] In the preferred technical solution of the present invention, the single-dose filling volume of the solution is 2ml-8ml.
[0028] In a preferred technical solution of the present invention, the solution is administered by atomization into the lungs and / or respiratory tract, preferably by atomization into the lungs and / or respiratory tract as an aerosol.
[0029] In a preferred technical solution of the present invention, the lyoprotectant is selected from any one of glucose, sucrose, galactose, mannitol, trehalose, sorbitol, glycerol, xylitol, polyethylene glycol, dextran, alanine, glycine, and arginine, or a combination thereof.
[0030] Another object of the present invention is to provide a method for preparing a composition for inhalation, wherein the composition contains a glucosamine compound (hereinafter referred to as a glucosamine compound) having a structure represented by Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
[0031]
[0032]
[0033] wherein R and R' are the same or different and are each independently selected from hydrogen, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted C1-C8 alkylcarbonyl, substituted or unsubstituted C6-C15 arylcarbonyl, substituted or unsubstituted C6-C15 aryloxycarbonyl, substituted or unsaturated 5-membered or 6-membered heterocyclylaminocarbonyl containing 1 to 3 heteroatoms selected from N, O and S,
[0034] The steps include:
[0035] (1) Weigh the required amount of glucosamine compound, add solvent, and stir at 25°C-50°C until dissolved;
[0036] (2) Add osmotic pressure regulator and stabilizer and stir until dissolved;
[0037] (3) Add a pH regulator to adjust the solution to pH 3.0-7.5, fix the volume, and filter to obtain the product.
[0038] In the preferred technical solution of the present invention, the "substituted" means that the substituent further contains 1 or 2 substituents selected from methyl, ethyl, propyl, methoxy, ethoxy, propoxy, methyl formate, ethyl formate, propyl formate, fluorine and chlorine.
[0039] In a preferred technical solution of the present invention, the substituents R and R' are the same or different and are independently selected from hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkylcarbonyl, substituted or unsubstituted C6-C10 arylcarbonyl, substituted or unsubstituted C6-C10 aryloxycarbonyl.
[0040] In a preferred technical solution of the present invention, the substituents R and R' are the same or different and are independently selected from hydrogen, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted C1-C4 alkylcarbonyl, substituted or unsubstituted C6-C8 arylcarbonyl, substituted or unsubstituted C6-C8 aryloxycarbonyl.
[0041] In a preferred technical solution of the present invention, the substituents R and R' are each independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methylcarbonyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, n-butylcarbonyl, isobutylcarbonyl, tert-butylcarbonyl, phenylcarbonyl, methylphenylcarbonyl, ethylphenylcarbonyl, propylphenylcarbonyl, isopropylphenylcarbonyl, n-butylphenylcarbonyl, isobutylphenylcarbonyl, tert-butylphenylcarbonyl, naphthylcarbonyl, methylnaphthylcarbonyl, ethylnaphthylcarbonyl, propylnaphthylcarbonyl, isopropylnaphthylcarbonyl, n-butylnaphthylcarbonyl, isobutylnaphthylcarbonyl, and tert-butylnaphthylcarbonyl.
[0042] In the preferred technical solution of the present invention, the glucosamine compound is selected from any one or a combination of compounds 1-6.
[0043]
[0044] In a preferred technical solution of the present invention, the pharmaceutically acceptable salt is selected from any one of hydrochloride, sulfate, nitrate, aminosulfonate, phosphate, citrate, tartrate, lactate, acetate, benzenesulfonate, p-toluenesulfonate, methanesulfonate, naphthalenesulfonate, ethanesulfonate, naphthalenedisulfonate, maleate, malate, fumarate, succinate, oxalate, and salicylate, or a combination thereof.
[0045] In a preferred technical solution of the present invention, the inhalation composition is selected from any one of a solid preparation or a liquid preparation.
[0046] In a preferred technical solution of the present invention, the pharmaceutically acceptable carrier is selected from any one of an osmotic pressure regulator, a stabilizer, a pH regulator, a solvent, and a lyoprotectant, or a combination thereof.
[0047] In a preferred technical solution of the present invention, the concentration of the glucosamine compound contained in the solution is 5 mg / ml-50 mg / ml, preferably 7.5 mg / ml-40 mg / ml, and more preferably 15 mg / ml-30 mg / ml.
[0048] In a preferred technical solution of the present invention, the osmotic pressure regulator is selected from any one of sodium chloride, potassium chloride, mannitol, glycerol, or a combination thereof.
[0049] In a preferred technical solution of the present invention, the osmotic pressure of the solution is 280mOsm / L-320mOsm / L.
[0050] In a preferred technical solution of the present invention, the stabilizer is selected from any one of disodium edetate, sodium sulfite, sodium metabisulfite, sodium bisulfite, vitamin C, ascorbyl palmitate, glycine, tryptophan, and lysine, or a combination thereof.
[0051] In a preferred technical solution of the present invention, the concentration of the stabilizer is 0.01-15 mg / ml, preferably 0.03-10 mg / ml, and more preferably 0.05-5 mg / ml.
[0052] In a preferred technical solution of the present invention, the pH regulator is selected from any one of sodium hydroxide, hydrochloric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate, citric acid, sodium citrate, citric acid, sodium citrate, malic acid, sodium malate, or a combination thereof.
[0053] In a preferred technical solution of the present invention, the solution has a pH of 3.0-8.0, preferably pH 4.0-7.5, and more preferably pH 5.0-7.0.
[0054] In a preferred technical solution of the present invention, the solvent is selected from any one of water, water for injection or a mixed solvent consisting of water and other co-solvents.
[0055] In a preferred technical solution of the present invention, after the solution is atomized, the mass median aerodynamic diameter (MMAD) is 2 μm-5 μm.
[0056] In a preferred technical solution of the present invention, after the solution is atomized, the fine particle size fraction (FPF) is 30%-70%.
[0057] In the preferred technical solution of the present invention, the single-dose filling volume of the solution is 2ml-8ml.
[0058] In a preferred technical solution of the present invention, the solution is administered by atomization into the lungs and / or respiratory tract, preferably by atomization into the lungs and / or respiratory tract as an aerosol.
[0059] In a preferred technical solution of the present invention, the lyoprotectant is selected from any one of glucose, sucrose, galactose, mannitol, trehalose, sorbitol, glycerol, xylitol, polyethylene glycol, dextran, alanine, glycine, and arginine, or a combination thereof.
[0060] Another object of the present invention is to provide use of the inhalation composition in preparing antiviral drugs.
[0061] In a preferred technical solution of the present invention, the virus is selected from any one of influenza virus, coronavirus, adenovirus, cytomegalovirus, coxsackie virus, measles virus, parainfluenza virus, or a combination thereof.
[0062] In a preferred technical solution of the present invention, the influenza virus is selected from any one of influenza A virus and influenza B virus, or a combination thereof.
[0063] In a preferred technical solution of the present invention, the coronavirus is selected from any one of SARS-CoV-1, SARS-CoV-2, MERS, 229E, NL63, OC43, HKU1, or a combination thereof.
[0064] Another object of the present invention is to provide an inhalation composition for use in preparing a medicament for use against SARS-CoV-2 virus and its mutant strains.
[0065] In a preferred technical solution of the present invention, the inhalation composition is used to treat or prevent infection caused by SARS-CoV-2 virus and its mutant strains in mammals.
[0066] In a preferred technical solution of the present invention, the mammal includes any one of bovines, equines, ovines, porcines, canines, felines, rodents, and primates, preferably any one of humans, cats, dogs, and pigs.
[0067] Another object of the present invention is to provide use of the inhalation composition for preparing a medicament for preventing and treating osteoarthritis.
[0068] In a preferred embodiment of the present invention, osteoarthritis is selected from any one of knee arthritis, hip arthritis, spondylitis, periarthritis of the shoulder, hand osteoarthritis, wrist osteoarthritis, ankle arthritis, or any of their complications.
[0069] Another object of the present invention is to provide a pharmaceutical composition comprising the inhalation composition of the present invention and any one or a combination of antiviral drugs and antibacterial drugs, and the composition is administered sequentially, successively, or simultaneously.
[0070] In the preferred technical scheme of the present invention, the antiviral drug or antibacterial drug is selected from α-interferon, β-interferon, γ-interferon, interferon α-1b, interferon-α2b, albumin, immunoglobulin G, CR3022 (macromolecule monoclonal antibody drug), favipiravir, remdesivir, oseltamivir phosphate, baloxavir, hydroxychloroquine, hydroxychloroquine phosphate, lopinavir, ritonavir, ribavirin, arbidol, arbidol hydrochloride, amoxicillin, azithromycin, cephalexin, cefuroxime axetil, cefixime, cefdinir, glucocorticoids, Huoxiang Zhengqi Capsules, Huoxiang Zhengqi Pills, Huoxiang Zhengqi Water, Huoxiang Zhengqi Oral Liquid, Jinhua Qinggan Granules, Lianhua Qingwen Capsules, Lianhua Qingwen Granules, Shufeng Jiedu Capsules, Shufeng Jiedu Granules, Fangfeng Tongsheng Pills, Fangfeng Tongsheng Granules or any one of them or a combination thereof.
[0071] The "median aerodynamic diameter (MMAD)" mentioned in the present invention refers to the unit density (ρ0 = 1 g / cm 3 The diameter of a sphere with a diameter of 1.5 mm (0.13 in) at which it reaches the same terminal sedimentation velocity (Vs) as that of the actual particle when moving at a low Reynolds number in still air is measured using device 3 (next generation impactor, NGI) in accordance with the method for determining the aerodynamic characteristics of fine ions of inhalation preparations in the 2020 edition of the Chinese Pharmacopoeia 0951.
[0072] Unless otherwise specified, when the present invention relates to the percentage between liquids, the percentages are volume / volume percentages; when the present invention relates to the percentage between liquids and solids, the percentages are volume / weight percentages; when the present invention relates to the percentage between solids and liquids, the percentages are weight / volume percentages; and the rest are weight / weight percentages.
[0073] Compared with the prior art, the present invention has the following beneficial technical effects:
[0074] 1. The inhaled glucosamine compound solution (glucosamine solution) of the present invention has scientifically screened components and ratios, and has a reasonable particle size distribution after atomization. After inhalation through the mouth and nose, it is administered by atomization and / or targeted administration by atomized aerosol, directly acting on the lungs and / or lower respiratory tract, significantly improving the deposition effect, targeting and bioavailability of the drug in the lungs and / or lower respiratory tract, reducing unnecessary systemic drug exposure, avoiding adverse reactions caused by gastrointestinal administration, and improving the effectiveness, safety, convenience and patient compliance of the drug. It is especially suitable for people with swallowing difficulties such as the elderly and children, and has the advantages of high antiviral activity, long-term targeting, high safety and effectiveness, good stability, high bioavailability, and a wide range of applicable populations.
[0075] 2. The preparation method of the present invention has the advantages of simple operation, significantly shortening the production cycle, significantly reducing production costs, and being suitable for large-scale industrial production. DETAILED DESCRIPTION
[0076] The present invention will be further described below in conjunction with specific examples. These examples are intended to illustrate the present invention only and are not intended to limit the scope of the invention. The experimental methods in the following examples where specific conditions are not specified are generally based on conventional conditions or conditions recommended by the manufacturer.
[0077] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those familiar to those skilled in the art. Any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred embodiments and materials described herein are for illustrative purposes only.
[0078] Example 1 Preparation of D-glucosamine solution for inhalation of the present invention (specification 3ml: 45mg)
[0079] Composition of D-glucosamine solution for inhalation:
[0080] Element Dosage (g) D-Glucosamine 15 Edetate disodium 0.05 Sodium chloride 7.0 Water for injection Adjust volume to 1000ml
[0081] The preparation of D-glucosamine solution for inhalation comprises the following steps:
[0082] 1) Weigh the required amount of D-glucosamine, add 700 ml of water for injection, and stir at 20°C-40°C until dissolved. Then add the required amount of sodium chloride and disodium edetate and stir until dissolved.
[0083] 2) Add appropriate amount of hydrochloric acid and / or sodium hydroxide to adjust the solution to pH 5.5, then add water for injection to make up to 1000 ml, and filter aseptically to obtain the product.
[0084] Example 2: Preparation of D-glucosamine solution for inhalation of the present invention (Specification 3ml: 22.5mg)
[0085] Composition of D-glucosamine solution for inhalation:
[0086] Element Dosage (g) D-Glucosamine 7.5 Vitamin C 0.8 Sodium chloride 6.3 Water for injection Adjust volume to 1000ml
[0087] The preparation of D-glucosamine solution for inhalation comprises the following steps:
[0088] 1) Weigh the required amount of D-glucosamine, add 700 ml of water for injection, and stir at 30°C-50°C until dissolved. Then add the required amount of sodium chloride and vitamin C and stir until dissolved.
[0089] 2) Add appropriate amount of citric acid and / or sodium hydroxide to adjust the solution pH to 5.2, then add water for injection to make up to 1000 ml, and filter aseptically to obtain the product.
[0090] Example 3: Preparation of N-acetyl-glucosamine solution for inhalation of the present invention (Specifications 3 ml: 45 mg)
[0091] Composition of N-acetyl-glucosamine solution for inhalation:
[0092] Element Dosage (g) N-acetyl-glucosamine 15 Sodium bisulfite 5 Sodium chloride 6.3 Water for injection Adjust volume to 1000ml
[0093] The preparation of N-acetyl-glucosamine solution for inhalation comprises the following steps:
[0094] 1) Weigh the required amount of N-acetyl-glucosamine, add 600 ml of water for injection, and stir at 25°C-45°C until dissolved. Then add the required amount of sodium bisulfite and sodium chloride and stir until dissolved.
[0095] 2) Add appropriate amount of citric acid and / or sodium hydroxide to adjust the solution pH to 6.0, then add water for injection to make up to 1000 ml, and filter aseptically to obtain the product.
[0096] Example 4: Preparation of N-acetyl-glucosamine solution for inhalation of the present invention (Specification 3 ml: 22.5 mg) Composition of N-acetyl-glucosamine solution for inhalation:
[0097] Element Dosage (g) N-acetyl-glucosamine 7.5 Glycine 0.5 glycerin 21 Water for injection Adjust volume to 1000ml
[0098] The preparation of N-acetyl-glucosamine solution for inhalation comprises the following steps:
[0099] 1) Weigh the required amount of N-acetyl-glucosamine, add 600 ml of water for injection, and stir at 25°C-45°C until dissolved. Then add the required amount of glycerol and glycine and stir until dissolved.
[0100] 2) Add appropriate amount of citric acid and / or sodium citrate to adjust the solution pH to 5.0, then add water for injection to make up to 1000 ml, and filter aseptically to obtain the product.
[0101] Test Example 1 Stability study of the glucosamine solution for inhalation of the present invention
[0102] The glucosamine compound solutions for inhalation (glucosamine solutions) prepared in Examples 1-4 were placed at a high temperature of 60°C for 10 days, at a light intensity of 4500 lx±500 lx for 10 days, and in a nebulizer cup for 4 hours. The properties, osmotic pressure molar concentration, related substances and content of the glucosamine solutions were measured. The related substances and contents were determined by LC-MS / MS. The detection conditions are shown in Table 1, and the results are shown in Table 2.
[0103] Table 1
[0104]
[0105]
[0106] Table 2
[0107]
[0108]
[0109] Note: NMT: not more than
[0110] Test Example 2 Evaluation of the atomization characteristics of the glucosamine solution for inhalation of the present invention - APSD
[0111] A PARI Turbo boy compression nebulizer was used in combination with an LC PLUS nebulizer cup to determine the aerodynamic particle size distribution (APSD) of the inhalation solutions of Example 1 and Example 2 according to the method for determining the aerodynamic characteristics of fine particles (General Rule 0951 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0112] The next-generation impactor (NGI) is a device recommended by various pharmacopoeias for the analysis of APSD (appreciable droplet size distribution) of nebulized inhalation preparations. Based on particle size and inertia, particles of varying size ranges are deposited in different layers of collection trays. The active substance content in each collection tray is determined by high-performance liquid chromatography (HPLC) or other quantitative methods. The active substance content in each layer is input into the CITDAS software to generate parameters for evaluating the nebulization performance of nebulized inhalation solutions: mass median aerodynamic diameter (MMAD), fine particle fraction (FPF, <5 μm), and geometric standard deviation (GSD). APSD analysis can determine the droplet size distribution and, in theory, predict the proportion of drug deposition in the oral cavity, trachea, bronchi, and lungs. Mass median aerodynamic diameter and fine particle fraction are important parameters for comparing different nebulization systems. Their measurement simulates drug deposition from the oral cavity to the lungs and, to a certain extent, can reflect differences in clinical efficacy and side effects.
[0113] Assemble the aerodynamic particle size distribution measuring device NGI and place it horizontally. To ensure that the active ingredients in the atomized aerosol can be quantitatively recovered at a flow rate of 15L / min, place filter paper under the MOC (inside the impactor). Place the device in a cooling device (5°C), pre-cool for more than 90 minutes, measure the internal temperature of the impactor to 5°C, and then start the test (measure in a cooling cabinet). Perform a leak test to ensure that the device is sealed. Turn on the vacuum pump, connect the flow meter to the L-type connecting pipe, adjust the flow control valve so that the gas flow rate at the inlet of the L-type connecting pipe is 15L / min (±5%), and remove the flow meter.
[0114] Position the nebulizer in its intended orientation. Accurately dispense 3 mL of drug solution into the nebulizer cup. Connect the L-shaped connecting tube to the nebulizer nozzle using the interface adapter, ensuring all joints are sealed. Turn on the vacuum pump. Preset the nebulization time to 60 seconds using the respiratory controller, and control the nebulizer and exhaust valve to open simultaneously. After the desired nebulization time, turn off the nebulizer, wait 30 seconds, turn off the vacuum pump, and remove the impactor from the cooling unit.
[0115] Place the filter paper under the MOC layer in a beaker, add 20 ml of solvent, soak it fully, filter it, and take the filtrate as the test solution for measuring the MOC layer deposition amount; add 20 ml of solvent to the collection plates of the remaining layers respectively, shake it gently, filter it, and take the filtrate as the test solution for each layer. The deposition amount of the layer is determined by LC-MS / MS.
[0116] The particle size distribution was analyzed using CITDAS software (COPLEY) to obtain metrological parameters FPF, MMAD, and GSD. The results were expressed as mean ± SD. The results are shown in Table 3.
[0117] Table 3
[0118] Example FPF (%) MMAD (μm) GSD 1 30.56±5.34 2.71±0.56 2.19±0.36 2 37.56±6.28 3.10±0.71 2.23±0.21
[0119] Test Example 3 Investigation of the atomization delivery rate and total delivery amount of the glucosamine solution for inhalation of the present invention
[0120] PARI Turbo boy compression nebulizer, combined with LC PLUS nebulizer cup, was used to investigate the delivery rate and total delivery volume under the breathing patterns of adults and children according to the method for determining the delivery rate and total delivery volume under the general chapter 0111 of inhaled liquid preparations in Part IV of the Chinese Pharmacopoeia 2020 edition.
[0121] Take 3ml of glucosamine inhalation solution, shake it well, squeeze the ampoule, add the atomized inhalation solution of glucosamine to the atomizer cup, connect the atomizer cup to the compressor, turn on the respiratory simulator, set the time of the first stage to 1 minute, start the compressor at the beginning of the respiratory cycle, and turn off the compressor at the same time when the respiratory cycle ends. Use diluent to clean and recycle the filter paper and the filter paper device to the same 100ml volumetric flask, as the test solution, and detect the delivery rate. Then install the respiratory simulator, the filter paper device equipped with filter paper, the atomizer cup, and the supporting compressor in accordance with the law, turn on the respiratory simulator, set the time of the second stage to 20 minutes, start the compressor at the beginning of the respiratory cycle, and turn off the compressor at the same time when the respiratory cycle ends. Use diluent to clean and recycle the filter paper and the filter paper device to the same 100ml volumetric flask, as the test solution, and detect the remaining delivery amount. The sum of the delivery rate and the remaining delivery amount is the total amount delivered. The results are shown in Table 4.
[0122] Table 4
[0123] Example Delivery rate (mg / min) Total amount delivered (mg) 1 2.16±0.34 20.9±0.56 2 2.26±0.65 12.5±0.71
[0124] Test Example 4 Investigation of the bioavailability of the glucosamine solution for inhalation of the present invention
[0125] 72 SD male rats aged 6-8 weeks were randomly divided into a control group (18 rats) and a test group (high, medium and low dose groups, 18 rats in each group, a total of 54 rats). The control group was gavaged with N-acetyl-glucosamine (Chinese medicine reagent, dosage of 500 mg / kg). The test group was aerosolized inhalation of the inhalation glucosamine solution of Example 1 and divided into three groups: low dose (2 mg / kg), medium dose (22.5 mg / kg) and high dose (45 mg / kg). Each group was aerosolized inhalation administered for 15 minutes.
[0126] 5 min, 20 min and 2 h after administration, 0.10 ml of blood was collected from the orbital vein of the experimental animals. The whole blood was anticoagulated with sodium heparin and centrifuged (10,000 rpm, 5 min). The plasma portion was collected and stored at -40°C for testing.
[0127] The experimental animals were anesthetized and killed 5 minutes, 1 hour, and 2 hours after administration, with 6 animals in each group. Their body weights were measured and their lung tissues (including trachea) were removed. The lung tissues were washed with physiological saline, dried with filter paper, weighed, and stored at -40°C until testing.
[0128] According to the lung tissue / normal saline ratio of 1g / 5mL, the corresponding normal saline was added to the lung tissue, homogenized with a homogenizer, centrifuged (10000rpm, 10min), 100uL of the supernatant was taken and placed in a 1.5ml centrifuge tube, 20ul of the internal standard solution was accurately added, vortexed for 1min to mix, centrifuged at 12000rpm for 10min, and 100ul of the supernatant was taken and analyzed according to the LC-MS / MS method of Experimental Example 2. The results are shown in Table 5.
[0129] The results showed that at 5 and 20 minutes after oral administration of glucosamine, the drug concentration in lung tissue was significantly lower than that in the medium and high concentration nebulized inhalation groups (P<0.001). At 2 hours, the drug concentration in lung tissue of oral administration was significantly lower than that in the high-dose nebulized inhalation group, but there was no significant difference with the medium-dose nebulized group (P>0.05). The drug concentration in lung tissue of glucosamine showed a dose-dependent characteristic with nebulized inhalation, increasing with increasing dose.
[0130] Table 5
[0131]
[0132] Note: *The drug concentration at the corresponding time point of nebulized inhalation administration is significantly different from that of oral administration.
[0133] The above description of the specific embodiments of the present invention does not limit the present invention. Those skilled in the art can make various changes or modifications based on the present invention. As long as they do not depart from the spirit of the present invention, they should fall within the scope of protection of the claims of the present invention.
Claims
1. Use of a solution for inhalation in the preparation of an antiviral drug, the solution consisting of an aminoglucosamine compound and a pharmaceutically acceptable carrier, wherein: The glucosamine compound is selected from any one of compounds 1-6 or a pharmaceutically acceptable salt thereof, the concentration of the glucosamine compound in the solution is 5-50 mg / ml, the pH of the solution is 3.0-8.0, and the pharmaceutically acceptable carrier is selected from any one of an osmotic pressure regulator, a stabilizer, a pH regulator, a solvent, and a lyophilization protective agent or a combination thereof; ; Wherein, the pharmaceutically acceptable salt is selected from any one or a combination of hydrochloride, sulfate, nitrate, aminosulfonate, phosphate, citrate, tartrate, lactate, acetate, benzenesulfonate, p-toluenesulfonate, methanesulfonate, naphthalenesulfonate, ethanesulfonate, naphthalene disulfonate, maleate, malate, fumarate, succinate, oxalate, and salicylate.
2. The use according to claim 1, wherein the virus is selected from any one of influenza virus, coronavirus, coxsackie virus or a combination thereof.
3. The use according to claim 2, wherein the influenza virus is selected from any one of influenza A virus and influenza B virus or a combination thereof.
4. The use as claimed in claim 2, wherein the coronavirus is selected from any one of SARS-CoV-1, SARS-CoV-2, MERS, 229E, NL63, OC43, HKU1, or a combination thereof.
5. The use according to claim 1, wherein the pharmaceutically acceptable carrier consists of an osmotic pressure regulator, a stabilizer, a pH regulator and a solvent.
6. The use according to any one of claims 1 to 5, wherein the concentration of the glucosamine compound in the solution is 7.5 mg / ml to 40 mg / ml.
7. The use according to claim 6, wherein the concentration of the glucosamine compound in the solution is 15 mg / ml-30 mg / ml.
8. The use according to claim 5, wherein the osmotic pressure regulator is selected from any one of sodium chloride, potassium chloride, mannitol, glycerol or a combination thereof.
9. The use according to claim 8, wherein the osmotic pressure of the solution is 280 mOsm / L-320 mOsm / L.
10. The use according to claim 5, wherein the stabilizer is selected from any one of disodium edetate, sodium sulfite, sodium pyrosulfite, sodium bisulfite, vitamin C, ascorbyl palmitate, glycine, tryptophan, and lysine, or a combination thereof.
11. The use according to claim 10, wherein the concentration of the stabilizer in the solution is 0.01-15 mg / ml.
12. The use according to claim 11, wherein the concentration of the stabilizer in the solution is 0.03-10 mg / ml.
13. The use according to claim 12, wherein the concentration of the stabilizer in the solution is 0.05-5 mg / ml.
14. The use according to claim 5, wherein the pH regulator is selected from any one of sodium hydroxide, hydrochloric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate, citric acid, sodium citrate, malic acid, sodium malate or a combination thereof.
15. The use according to claim 5, wherein the solution has a pH of 4.0-7.
5.
16. The use according to claim 15, wherein the solution has a pH of 5.0-7.
0.
17. The use according to claim 5, wherein the solvent is water.
18. The use according to claim 17, wherein the solvent is water for injection.
19. The use according to claim 6, wherein after the solution is atomized, the mass median aerodynamic diameter (MMAD) is 2 μm-5 μm.
20. The use according to claim 6, wherein after the solution is atomized, the dosage of fine particles is 30%-70%.
21. The use according to claim 6, wherein the single-dose filling volume of the solution is 2 ml-8 ml.
22. The use according to claim 6, wherein the solution is administered by atomization into the lungs and / or respiratory tract.
23. The use according to claim 22, wherein the solution is administered via pulmonary and / or respiratory tract aerosol nebulization.
24. The use according to claim 6, wherein the preparation method of the solution comprises the following steps: (1) Weigh the required amount of glucosamine compound, add solvent, and stir at 25°C-50°C until dissolved; (2) Add the required amount of osmotic pressure regulator and stabilizer and stir until dissolved; (3) Add the required amount of pH adjuster to adjust the solution pH to 3.0-8.0, make up to volume, and filter to obtain the product.
25. Use of a solution for inhalation in the preparation of a drug for resisting SARS-CoV-2 virus and its mutant virus strains, wherein the solution is composed of a glucosamine compound and a pharmaceutically acceptable carrier, wherein: The glucosamine compound is selected from any one of compounds 1-6 or a pharmaceutically acceptable salt thereof, the concentration of the glucosamine compound in the solution is 5-50 mg / ml, the pH of the solution is 3.0-8.0, and the pharmaceutically acceptable carrier is selected from any one of an osmotic pressure regulator, a stabilizer, a pH regulator, a solvent, and a lyophilization protective agent or a combination thereof; ; Wherein, the pharmaceutically acceptable salt is selected from any one or a combination of hydrochloride, sulfate, nitrate, aminosulfonate, phosphate, citrate, tartrate, lactate, acetate, benzenesulfonate, p-toluenesulfonate, methanesulfonate, naphthalenesulfonate, ethanesulfonate, naphthalene disulfonate, maleate, malate, fumarate, succinate, oxalate, and salicylate.
26. The use according to claim 25, wherein the pharmaceutically acceptable carrier consists of an osmotic pressure regulator, a stabilizer, a pH regulator and a solvent.
27. The use according to any one of claims 25 to 26, wherein the concentration of the glucosamine compound in the solution is 7.5 mg / ml to 40 mg / ml.
28. The use according to claim 27, wherein the concentration of the glucosamine compound in the solution is 15 mg / ml-30 mg / ml.
29. The use according to claim 26, wherein the osmotic pressure regulator is selected from any one of sodium chloride, potassium chloride, mannitol, glycerol or a combination thereof.
30. The use according to claim 27, wherein the osmotic pressure of the solution is 280 mOsm / L-320 mOsm / L.
31. The use according to claim 26, wherein the stabilizer is selected from any one of disodium edetate, sodium sulfite, sodium pyrosulfite, sodium bisulfite, vitamin C, ascorbyl palmitate, glycine, tryptophan, and lysine, or a combination thereof.
32. The use according to claim 27, wherein the concentration of the stabilizer in the solution is 0.01-15 mg / ml.
33. The use according to claim 32, wherein the concentration of the stabilizer in the solution is 0.03-10 mg / ml.
34. The use according to claim 33, wherein the concentration of the stabilizer in the solution is 0.05-5 mg / ml.
35. The use according to claim 26, wherein the pH regulator is selected from any one of sodium hydroxide, hydrochloric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate, citric acid, sodium citrate, malic acid, sodium malate or a combination thereof.
36. The use according to claim 27, wherein the solution has a pH of 4.0-7.
5.
37. The use according to claim 36, wherein the solution has a pH of 5.0-7.
0.
38. The use according to claim 26, wherein the solvent is water.
39. The use according to claim 38, wherein the solvent is water for injection.
40. The use according to claim 27, wherein after the solution is atomized, the mass median aerodynamic diameter (MMAD) is 2 μm-5 μm.
41. The use according to claim 27, wherein after the solution is atomized, the dosage of fine particles is 30%-70%.
42. The use according to claim 27, wherein the single-dose filling volume of the solution is 2 ml-8 ml.
43. The use according to claim 27, wherein the solution is administered by aerosolization into the lungs and / or respiratory tract.
44. The use according to claim 43, wherein the solution is administered via pulmonary and / or respiratory tract aerosol nebulization.
45. The use according to claim 27, wherein the method for preparing the solution comprises the following steps: (1) Weigh the required amount of glucosamine compound, add solvent, and stir at 25°C-50°C until dissolved; (2) Add the required amount of osmotic pressure regulator and stabilizer and stir until dissolved; (3) Add the required amount of pH adjuster to adjust the solution pH to 3.0-8.0, make up to volume, and filter to obtain the product.
46. Use of a solution for inhalation in the preparation of a medicament for treating or preventing infection caused by SARS-CoV-2 virus and mutant strains thereof in mammals, the solution consisting of a glucosamine compound and a pharmaceutically acceptable carrier, wherein: The glucosamine compound is selected from any one of compounds 1-6 or a pharmaceutically acceptable salt thereof, the concentration of the glucosamine compound in the solution is 5-50 mg / ml, the pH of the solution is 3.0-8.0, and the pharmaceutically acceptable carrier is selected from any one of an osmotic pressure regulator, a stabilizer, a pH regulator, a solvent, and a lyophilization protective agent or a combination thereof; ; Wherein, the pharmaceutically acceptable salt is selected from any one or a combination of hydrochloride, sulfate, nitrate, aminosulfonate, phosphate, citrate, tartrate, lactate, acetate, benzenesulfonate, p-toluenesulfonate, methanesulfonate, naphthalenesulfonate, ethanesulfonate, naphthalene disulfonate, maleate, malate, fumarate, succinate, oxalate, and salicylate.
47. The use according to claim 46, wherein the pharmaceutically acceptable carrier consists of an osmotic pressure regulator, a stabilizer, a pH regulator and a solvent.
48. The use according to any one of claims 46 to 47, wherein the concentration of the glucosamine compound in the solution is 7.5 mg / ml to 40 mg / ml.
49. The use according to claim 48, wherein the concentration of the glucosamine compound in the solution is 15 mg / ml-30 mg / ml.
50. The use according to claim 47, wherein the osmotic pressure regulator is selected from any one of sodium chloride, potassium chloride, mannitol, glycerol or a combination thereof.
51. The use according to claim 48, wherein the osmotic pressure of the solution is 280 mOsm / L-320 mOsm / L.
52. The use according to claim 47, wherein the stabilizer is selected from any one of disodium edetate, sodium sulfite, sodium pyrosulfite, sodium bisulfite, vitamin C, ascorbyl palmitate, glycine, tryptophan, and lysine, or a combination thereof.
53. The use according to claim 48, wherein the concentration of the stabilizer in the solution is 0.01-15 mg / ml.
54. The use according to claim 53, wherein the concentration of the stabilizer in the solution is 0.03-10 mg / ml.
55. The use according to claim 54, wherein the concentration of the stabilizer in the solution is 0.05-5 mg / ml.
56. The use according to claim 47, wherein the pH regulator is selected from any one of sodium hydroxide, hydrochloric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate, citric acid, sodium citrate, malic acid, sodium malate, or a combination thereof.
57. The use according to claim 48, wherein the solution has a pH of 4.0-7.
5.
58. The use according to claim 57, wherein the solution has a pH of 5.0-7.
0.
59. The use according to claim 47, wherein the solvent is water.
60. The use according to claim 59, wherein the solvent is water for injection.
61. The use according to claim 48, wherein after the solution is atomized, the mass median aerodynamic diameter (MMAD) is 2 μm-5 μm.
62. The use according to claim 48, wherein after the solution is atomized, the dosage of fine particles is 30%-70%.
63. The use according to claim 48, wherein the single-dose filling volume of the solution is 2 ml-8 ml.
64. The use according to claim 48, wherein the solution is administered by aerosolization into the lungs and / or respiratory tract.
65. The use according to claim 64, wherein the solution is administered via pulmonary and / or respiratory tract aerosol nebulization.
66. The use according to claim 48, wherein the method for preparing the solution comprises the following steps: (1) Weigh the required amount of glucosamine compound, add solvent, and stir at 25°C-50°C until dissolved; (2) Add the required amount of osmotic pressure regulator and stabilizer and stir until dissolved; (3) Add the required amount of pH adjuster to adjust the solution pH to 3.0-8.0, make up to volume, and filter to obtain the product.
